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Abstract 
Aims/hypothesis: Soluble tumor necrosis factor receptors 1 and 2 (sTNFR1 and sTNFR2) contribute to experimental 
diabetic kidney disease, a condition with substantially increased cardiovascular risk when present in patients. There-
fore, we aimed to explore the levels of sTNFRs, and their association with prevalent kidney disease, incident cardio-
vascular disease, and risk of mortality independently of baseline kidney function and microalbuminuria in a cohort 
of patients with type 2 diabetes. In pre-defined secondary analyses we also investigated whether the sTNFRs predict 
adverse outcome in the absence of diabetic kidney disease.
Methods: The CARDIPP study, a cohort study of 607 diabetes patients [mean age 61 years, 44 % women, 45 cardio-
vascular events (fatal/non-fatal myocardial infarction or stroke) and 44 deaths during follow-up (mean 7.6 years)] was 
used.
Results: Higher sTNFR1 and sTNFR2 were associated with higher odds of prevalent kidney disease [odd ratio (OR) per 
standard deviation (SD) increase 1.60, 95 % confidence interval (CI) 1.32–1.93, p < 0.001 and OR 1.54, 95 % CI 1.21–
1.97, p = 0.001, respectively]. In Cox regression models adjusting for age, sex, glomerular filtration rate and urinary 
albumin/creatinine ratio, higher sTNFR1 and sTNFR2 predicted incident cardiovascular events [hazard ratio (HR) per 
SD increase, 1.66, 95 % CI 1.29–2.174, p < 0.001 and HR 1.47, 95 % CI 1.13–1.91, p = 0.004, respectively]. Results were 
similar in separate models with adjustments for inflammatory markers, HbA1c, or established cardiovascular risk fac-
tors, or when participants with diabetic kidney disease at baseline were excluded (p < 0.01 for all). Both sTNFRs were 
associated with mortality.
Conclusions/Interpretations: Higher circulating sTNFR1 and sTNFR2 are associated with diabetic kidney disease, 
and predicts incident cardiovascular disease and mortality independently of microalbuminuria and kidney function, 
even in those without kidney disease. Our findings support the clinical utility of sTNFRs as prognostic markers in type 
2 diabetes.
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Background
Diabetes is one of the most important risk factors for 
cardiovascular disease [1, 2], and the risk of cardiovas-
cular events and complications is substantially higher in 
those with diabetic kidney disease than in those without 
[3]. Soluble receptors for tumor necrosis factor (TNF)-α 
(sTNFRs (sTNFR1 and sTNFR2)), have been suggested to 
be important factors underpinning the development of 
diabetic kidney disease in experimental studies [4].
The sTNFRs have earlier been shown to be cross-sec-
tionally associated with lower glomerular filtration rate 
(GFR) [5], and higher levels of low grade albuminuria in 
patients with type 2 diabetes [6, 7], as well as ESRD in 
American Indians with type 2 diabetes [8]. Higher lev-
els of sTNFR2 has also seen on obese than in non-obese 
patients with type 2 diabetes [9]. Furthermore, in clinical 
studies in type 1 diabetes, levels of the sTNFRs predict 
the progression from micro- to macro-albuminuria [10], 
microalbuminuria and GFR decline [11, 12], and develop-
ment of CKD stage 3 [13]. Yet, initiation of antidiabetic 
therapy did not seem to reduce the levels of sTNFR1 or 
sTNFR2 in in a randomized trial of patients with type 2 
diabetes [14].
High levels of sTNFR1 have been associated with 
increased risk for mortality in various settings such as in 
patients with rheumatoid arthritis [15], in chronic kidney 
disease [16], and in the community [17, 18]. Higher lev-
els of sTNFR1 has also been associated with ESRD and 
mortality in type 2 diabetes [19]. In addition, sTNFR1 
and sTNFR2 have been associated with ESRD [20], and as 
sTNFR1 and sTNFR2 as risk markers for cardiovascular 
death in type 2 diabetes patients [21]. Moreover, higher 
levels of sTNFR2 have been shown to be associated with 
coronary heart disease in women with diabetes [22]. 
Whether this association is mediated by kidney damage 
or dysfunction has not been reported.
We hypothesized that sTNFR1 and sTNFR2 are impor-
tant factors in the development of diabetic kidney dis-
ease and cardiovascular disease in patients with type 2 
diabetes. Accordingly, we aimed to explore the levels 
of sTNFRs, and their association with prevalent kid-
ney disease, incident cardiovascular disease, and risk of 
mortality independently of baseline kidney function and 
microalbuminuria in a cohort of patients with type 2 dia-
betes. In pre-defined secondary analyses we also inves-
tigated whether the sTNFRs predict adverse outcome in 
the absence of diabetic kidney disease.
Methods
Data from the cardiovascular risk factors in patients with 
diabetes: a Prospective Study in Primary Care (CARDIPP) 
was analyzed. The study was launched in 2005 and base-
line data collection was completed in November 2008. 
The general aim of CARDIPP was to investigate cardio-
vascular risk factors in middle-aged patients with type 2 
diabetes to facilitate early and individually adjusted risk 
intervention. Patients aged 55–65  years were consecu-
tively recruited during their usual annual follow-ups at 22 
primary healthcare centers in the counties of Östergöt-
land and Jönköping, Sweden, irrespective of their previ-
ous blood pressure and CVD status. The centers varied 
in size and were located in different geographical areas, 
but all followed the national guidelines for diabetes care. 
Patients with severe other concomitant diseases such as 
cognitive impairment and cancer were not included. Yet, 
we did not exclude patients with severe kidney dysfunc-
tion or massive proteinuria.
A questionnaire was used to gain information about 
lifestyle habits, including alcohol consumption and 
smoking status, while a standardized medical history 
provided data on diabetes duration, medications and pre-
vious cardiovascular events.
One single spot urine and blood samples for laboratory 
analyses were taken in the morning following at least 10 h 
of fasting. Blood samples for the laboratory analyses were 
collected at the healthcare centers. Clinical data such as 
body weight, height and waist circumference were also 
recorded at each primary healthcare center.
Blood pressure was calculated as the average of three 
sitting measurements taken 1-min apart by specially 
trained nurses at each primary healthcare center.
Altogether, CARDIPP enrolled 761 participants, out 
of whom 58 had missing serum samples in the biobank. 
An additional 71 individuals had suffered a myocar-
dial infarction or stroke prior to the baseline and were 
excluded from the present analyses. After exclusion of 
individuals with missing data on estimated GFR (eGFR) 
or albumin-creatinine ratio (ACR) at the baseline, 607 
individuals remained in the present analyses.
The present study was approved by the regional eth-
ics review board based in Linköping, and all participants 
gave their written informed consent.
Laboratory analyses
The Swedish standard high-performance liquid chroma-
tography (HPCL) Mono-S method was used to measure 
HbA1c, although the data were then converted to Diabe-
tes Control and Complications Trial (DCCT) standards 
(%) and International Federation of Clinical Chemis-
try and Laboratory Medicine (IFCC) units (mmol/mol). 
Serum and urine creatinine were measured at the local 
clinical chemistry laboratory (SWEDAC accredited Lab 
Med in Östergötland, Sweden) using an IDMS calibrated 
modified Jaffe method on an Advia 1800 analyzer (Sie-
mens Healthcare Diagnostics). Coefficients of variation 
(CV) for the creatinine method was 4.3 % at 90 μmol/L 
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and 3.1 % at 380 μmol/L. Urine albumin was analyzed on 
the same instrument as creatinine using reagents from 
Siemens Healthcare Diagnostics.
Glomerular filtration rate (eGFR) was estimated using 
the CKD-EPI formula, and urinary ACR was used as 
a measure of albuminuria. Kidney dysfunction was 
defined as having an eGFR <60  mL/min/1.73  m2 and 
microalbuminuria was defined as having ACR <3 (g/
mol). Diabetic kidney disease was defined as having kid-
ney dysfunction and/or microalbuminuria at baseline. 
C-reactive protein (CRP) was measured using a high sen-
sitive latex-enhanced turbidimetric immunoassay (Roche 
Diagnostics, Mannheim, Germany) with a lower limit of 
detection of 0.03 mg/L. The coefficient of variation (CV) 
for the CRP assay was 4.5 %. Plasma levels of IL-6 were 
measured with an ultrasensitive cytokine bead kit (Invit-
rogen Co, Carlsbad, CA, USA) according to the manufac-
turer’s instructions and analyzed on a Luminex® 100TM 
system (Austin, TX, USA). The limit of detection was 
0.84  pg  mL-1 for IL-6. The intra-assay CV was 5–12  % 
and the inter-assay CV was 17–20 %.
Blood and urine samples were frozen for later analy-
ses, and the soluble receptors, sTNFR1 and sTNFR2 were 
analyzed using commercially available ELISA kit (DY225 
and DY726, R and D Systems, Minneapolis, MN). The 
assays had a total CV of approximately 6 %. All laboratory 
tests were performed blinded without any knowledge of 
patient outcome.
Follow‑up of outcomes
Incident cardiovascular disease was defined as having a 
fatal or non-fatal myocardial infarction or stroke diagno-
sis (International Classification of Diseases, ICD-10 I21 
or I63, respectively) recorded in the National In-Hospi-
tal Care Register, or any mortality due to cardiovascular 
causes in the National Cause of Death Register (ICD 10: 
I00–I99). Total mortality was defined as being registered 
with a death-date in the National Cause of Death Regis-
ter. There was no loss of follow-up.
Statistical analyses
In cross-sectional analyses, medians and their confi-
dence intervals were estimated with Bonett-Price 95  % 
confidence intervals (CI). Spearman correlation tests 
were used to study the correlation between sTNFR1 and 
sTNFR2, as well as between the receptors and the estab-
lished kidney disease measures eGFR and ACR. Age- and 
sex adjusted logistic regression was used to calculate the 
odds ratios (OR) for having prevalent kidney dysfunction, 
microalbuminuria or kidney disease at baseline.
In longitudinal analyses, Cox regression was used to 
calculate hazard ratios (HR) with 95  % CI, and Laplace 
regression was used to calculate the difference in time (in 
years) until 5  % of the individuals had a cardiovascular 
event or died during follow up [23]. Bootstrap methods 
were used to calculate the 95  % CIs in Laplace Regres-
sion, with an amendment for Laplace regression to Stata 
(College Station, Texas, USA), version 11.2. We modelled 
sTNFR1 and sTNFR2 as per SD increment.
To limit the risk of overfitting, the following two multi-
variable models were used:
Model A: adjusted for age, and sex.
Model B: adjusted for age, sex, eGFR and ACR (pri-
mary model).
In secondary models we also added the following 
adjustments to model A: inflammation [CRP and IL-6 
(Model C)], diabetes treatment [HbA1c, and diabetes 
treatment (diet, oral antidiabetics or insulin) (Model D)], 
and all factors in model B and established cardiovascular 
risk factors (smoking, LDL-cholesterol, HDL-cholesterol, 
systolic blood pressure), cardiovascular medication, anti-
hypertensive medication [ACE-inhibitors/ARBs, calcium 
channel blockers, beta blockers and diuretics], and lipid 
lowering treatment (statins)], (Model E).
Multiple imputation were used to account for missing 
data for co-variates in the Cox regression analyses. As 
a secondary analysis, we analyzed the risks for incident 
cardiovascular disease and mortality in individuals with-
out diabetic kidney disease at baseline (n = 467).
We also mirrored the cardiovascular risk with higher 
levels of sTNFR1 and sTNFR2 using spline-curves.
Results
Baseline characteristics are shown in Table 1. The mean 
level of sTNFR1 was 2701 (standard deviation (SD) 
854) ng/l, and the mean sTNFR2 was 6383 (SD 2120) ng/l.
Cross‑sectional analyses
The correlation between sTNFR1 and sTNFR2 was 
R  =  0.72 (p  <  0.001). Both receptors were also statisti-
cally significantly correlated with eGFR; correlation 
with sTNFR1 was R  =  −0.21 (p  <  0.001), and sTNFR2 
R = −0.21 (p < 0.001). Weak correlations with low grade 
albuminuria were seen; sTNFR1 R =  0.098 (p =  0.015), 
and sTNFR2 R = 0.052 (p = 0.20).
Logistic regression models for the age and sex adjusted 
association between SD increments in sTNFR1 and 
sTNFR2, and kidney dysfunction, microalbuminuria and 
diabetic kidney disease are shown in Table 2. Both recep-
tors were significantly associated with all three kidney 
phenotypes.
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Longitudinal analyses
During follow-up (mean 7.4  years) a total of 45 partici-
pants had an incident cardiovascular event and 44 par-
ticipants died (incidence rate 1.00 (95  % CI 0.74–1.34) 
and 0.94 (95  % CI 0.71–1.28) per 100 person years of 
follow-up, respectively (16 died of cardiovascular causes, 
16 died of cancer, 3 died of diabetes, and 9 died of other 
causes). In the subsample without diabetic kidney disease 
at baseline (n = 467), 27 participants had an incident car-
diovascular event and (mean 7.6  years) 32 participants 
died (incidence rate 0.77 (95  % CI 0.53–1.13) and 0.90 
(95  % CI 0.64–1.27) per 100 person years of follow-up, 
respectively).
Cox regression models of the risk of incident cardiovas-
cular events associated with increments in sTNFR1 and 
sTNFR2 are shown in Table 3 in all individuals as well as 
in those without kidney disease at baseline. Higher risk 
estimates were seen with higher levels of both recep-
tors, in primary multivariable models (Model A–D). The 
spline curves (Fig. 1) suggest no deviation from linearity 
in the association between the sTNFRs and cardiovascu-
lar events. In participants without kidney disease at base-
line, both sTNFR1 and sTNFR2 predicted cardiovascular 
events in all multivariable models (Table 3).
In Laplace regression models adjusted for age, sex, 
GFR and low grade albuminuria (Model B) a stand-
ard deviation higher level of sTNFR1 and sTNFR2 was 
associated with a shorter estimated time until 5 % of the 
participants suffered an incident cardiovascular disease 
event: (1.65 years, (95 % CI 3.02–0.28 years), p =  0.018 
and 1.38  years (95  % CI 2.14–0.62  years), p  <  0.001, 
respectively.
The Cox regression risk estimates for the association 
between sTNFR1 and sTNFR2 and total mortality associ-
ated with standard deviation increments in sTNFR1 and 
sTNFR2 are shown in Table 4 in all individuals as well as 
in those without kidney disease at baseline. Higher risks 
were seen with higher levels of both receptors, but the 
risk estimates were slightly higher for sTNFR2 than for 
sTNFR1. The elevated risks were statistically significant 
in all models tested.
In Laplace regression models adjusted for age, sex, 
smoking, eGFR and low grade albuminuria (Model B) a 
standard deviation higher level of sTNFR1 was associated 
with a shorter estimated time until 5 % of the participants 
died: 1.85  years, (95  % CI 2.83–0.88  years), p  <  0.001. 
Using Model B, but sTNFR2 instead of sTNFR1, one 
standard deviation higher levels of sTNFR2 was associ-
ated with 2.35 years (95 % CI 3.53–1.17 years), p < 0.001, 
until the first 5 % died.
There were no missing in model A and model B, but the 
imputed missing data were useful in other models, where 
complete data on all variables was available for: model C 
n = 586, model D n = 604, and model E n = 559.
Discussion
In the present study, higher levels of both sTNFR1 and 
sTNFR2 were associated with prevalent diabetic kid-
ney disease. Yet, both sTNFRs robustly predicted inci-
dent cardiovascular events independently of age, sex, 
and established kidney disease measures. The results 
were also significant in separate models adjusted for 
cardiovascular risk factors, cardiovascular medication, 
Table 1 Baseline characteristics
n (%) or median (95 % Bonett‑Price confidence interval)
Number of subjects 607
Men, n. (%) 399 (66 %)
sTNFR1 (ng/l) 2567 (2488–2645)
sTNFR2 (ng/l) 6010 (5818–6202)
Age (years) 61 (60.5–61.5)
Current smoking 108 (18 %)
Glomerular filtration (ml/min/1.73 m2) 77 (75–78)
GFR <60 ml/min/1.73 m2 58 (10 %)
Albumin-creatinine ratio (g/mol) 0.60 (0.50–0.70)
Microalbuminuria 94 (15 %)
Diabetic kidney disease 140 (23 %)
Systolic blood pressure (mmHg) 137 (135–138)
Diastolic blood pressure (mmHg) 80 (79–81)
HbA1c (IFCC, mmol/mol) 54 (53–56)
LDL-cholesterol (mmol/l) 2.7 (2.6–2.8)
HDL-cholesterol (mmol/l) 1.2 (1.15–1.25)
High sensitivity C-reactive protein (mg/l) 1.60 (1.35–1.85)
Interleukin-6 (ng/l) 2.15 (1.99–2.31)
Statin treatment 327 (53 %)
Antihypertensive treatment 390 (64 %)
Table 2 Logistic regression models for  the age and  sex 
adjusted association between  sTNFR1 and  sTNFR2, 
and kidney dysfunction (GFR <60 ml/min/1.73 m2, n = 58), 
microalbuminuria (n  =  94), or diabetic kidney disease 
(either low kidney dysfunction, microalbuminuria, or 
both n = 140)
Odds ratio (per SD) 95 % CI p value
sTNFR1
 GFR <60 ml/min/1.73 m2 1.87 1.47–2.38 <0.001
 Microalbuminuria 1.32 1.07–1.63 0.009
 Diabetic kidney disease 1.60 1.32–1.93 <0.001
sTNFR2
 GFR <60 ml/min/1.73 m2 1.54 1.21–1.97 0.001
 Microalbuminuria 1.36 1.10–1.67 0.004
 Diabetic kidney disease 1.43 1.19–1.71 <0.001
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inflammatory markers, and HbA1c. Interestingly, both 
receptors were associated with an increased risk also in 
those without kidney disease at baseline indicating that 
sTNFR1 and sTNFR2 portray prognostic information 
prior to the development of overt diabetic nephropathy. 
Robust associations with total mortality were also seen 
for both sTNFR1 and sTNFR2.
Comparisons with other studies
In line with previous studies in type 2 diabetes patients, 
high levels of sTNFR1 and sTNFR2 were associated with 
worsened kidney function and higher urinary albumin/
creatinine ratio [5–7, 24].
As summarized in the introduction, some evidence of 
adverse outcomes in type 2 diabetes has been published. 
Higher levels of sTNFR1 was associated with increased 
mortality risk in patients with type 2 diabetes and kidney 
disease [21]. Another trial showed that higher sTNFR2 
predicted coronary heart disease in females with type 
2 diabetes [22], yet, the authors of that study did not 
investigate whether the results were significant after 
adjustments for kidney function or albuminuria, which is 
the novelty of the present study. We also showed that the 
associations were present in individuals without preva-
lent kidney disease.
Potential mechanistic pathways for our observations
The association between sTNFR1 and sTNFR2 and inci-
dent cardiovascular disease could be explained by their 
atherosclerotic effects, or by being markers of systemic 
inflammation [22, 25]. Inflammation plays a vital part 
Table 3 Multivariable Cox regression models showing 
the association between  sTNFR1 and  sTNFR2, with  major 
cardiovascular events in all individuals and in those with-
out kidney disease
Model A: adjusted for age, and sex; Model B: adjusted for age, sex, eGFR and 
ACR; Model C: adjusted for age, sex, CRP IL-6; Model D: adjusted for age, sex, 
HbA1c, and diabetes treatment (diet, oral antidiabetics or insulin); Model E 
(secondary analysis): established cardiovascular risk factors (smoking, LDL-
cholesterol, HDL-cholesterol, systolic blood pressure), cardiovascular medication, 
antihypertensive medication (ACE-inhibitors/ARBs, calcium channel blockers, 
beta blockers and diuretics), and lipid lowering treatment (statins), to model B





sTNFR1 all A 1.68 (1.33–2.13) <0.001
B 1.66 (1.29–2.14) <0.001
C 1.61 (1.26–2.06) <0.001
D 1.65 (1.29–2.11) <0.001
E 1.79 (1.39–2.14) <0.001
Without kidney 
disease
A 1.88 (1.42–2.25) <0.001
B 1.94 (1.47–2.56) <0.001
C 1.77 (1.32–2.39) <0.001
D 1.85 (1.39–2.47) <0.001
E 2.06 (1.51–2.82) <0.001
sTNFR2 all A 1.51 (1.17–1.93) 0.001
B 1.47 (1.13–1.91) 0.004
C 1.44 (1.10–1.88) 0.008
D 1.46 (1.13–1.89) 0.004
E 1.48 (1.14–1.93) 0.003
Without kidney 
disease
A 1.67 (1.25–2.25) 0.001
B 1.72 (1.29–2.28) <0.001
C 1.56 (1.13–2.17) 0.008
D 1.70 (1.26–2.30) 0.001
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Fig. 1 Regression spline curves with 95 % confidence intervals of the 
unadjusted association between higher levels of sTNFR1 and sTNFR2 
with the risk of cardiovascular disease
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in the formation of the atherosclerotic lesion, as well as 
in plaque rupture; the final trigger of most ischemic car-
diovascular events [26]. However, the associations with 
incident cardiovascular disease were independent of 
established cardiovascular risk factors, including hsCRP 
and IL6, showing that levels of sTNFRs may provide 
additional information in cardiovascular prediction.
Hyperglycemia has been shown to affect the levels of 
oxidative stress [27, 28]. Oxidative stress increase the 
overall TNF-α system activity [27], especially sTNFR2 
[29]. Hyperglycemia may also cause arterial stiffness. 
Pulse wave velocity is a common surrogate for arterial 
stiffness and has been shown to be highly correlated with 
the levels of sTNFR1 and sTNFR2 [30].
Higher levels of sTNFR1 and sTNFR2 have been shown 
to be associated with development of ESRD in patients 
with type-1 diabetes without proteinuria [12], as well 
as risk for early renal decline in individuals with type-1 
diabetes with normal renal function (and no proteinu-
ria) [13]. A more rapid decline in kidney function and 
development of diabetes nephropathy may thus explain 
the associations between sTNFR1 and sTNFR2 with car-
diovascular events and with mortality that we observed, 
as rapid progression of nephropathy has been associ-
ated with poor prognoses in individuals with diabetes 
[3, 4]. It should also be noted that the sTNFRs predicted 
adverse outcome independently of HbA1c which sug-
gest that poor glucose control is not a main driver of the 
associations.
The association between sTNFR1 and sTNFR2 and 
mortality may have several explanations, as TNF-α and 
its soluble receptors are important in several elementary 
pathological processes not only in cardiovascular disease 
but also cancer [31, 32]. In fact, higher levels of sTNFR1 
and sTNFR2 are likely to be associated with lower cancer 
survival [33–35]. The joint action of interferon-gamma 
and TNF-α may lead to cell cycle arrest in most cancers, 
however, this phenomenon requires the tumor to express 
sTNFR1 [36]. The role of sTNFR1 and sTNFR2 as risk 
factors of cause-specific mortality in individuals with dia-
betes requires further studies in larger study samples.
Clinical implications
Given the ongoing global diabetes epidemic it will be 
of increasing importance in the future to discriminate 
between those patients with an increased risk of a rapid 
progression to complications and death, from those 
with a slow and more benign progression. Our findings 
put forward that high levels of sTNFRs are potentially 
useful markers of poor prognosis in type 2 diabetes, 
in addition to their potential use as markers of kidney 
function decline, progression of chronic kidney disease 
and nephropathy [10–13, 37]. The TNF superfamily, 
with TNF-alpha, sTNFR1 and sTNFR2, TNF-like weak 
inducer of apoptosis (sTWEAK) [38], tumor necrosis fac-
tor receptor superfamily member 6 [39], Tumor necrosis 
factor ligand superfamily member 14 (TNFSF14) [40], 
and other member proteins are a part of a complex inter-
play; and that different ways to clinically target these 
pathways are possible. The biguanide buformin, which is 
closely related to the most commonly used antidiabetic 
drug metformin was not associated with any changes in 
the levels of sTNFR1, in a study of obese patients with 
type 2 diabetes where buformin was compared to lifestyle 
changes [41]. However, pioglitazone was associated with 
fewer cardiovascular events in the PROspective piogl-
itAzone Clinical Trial In macroVascular Events (PROac-
tive study) [42], and mechanistic studies in humans have 
shown that pioglitazone can modulate the increased 
activity of TNF-α converting enzyme, in patients with 
type 2 diabetes and obesity [43]. Moreover, aspirin has 
been shown to reduce TNF-α in patients with type 2 dia-
betes [44]. Anti-TNF therapy has been studied in patients 
Table 4 Multivariable Cox regression models showing the 
association between  sTNFR1 and  sTNFR2, with  mortality 
in all individuals and in those without kidney disease
Model A: adjusted for age, and sex; Model B: adjusted for age, sex, eGFR and 
ACR; Model C: adjusted for age, sex, CRP IL-6; Model D: adjusted for age, sex, 
HbA1c, and diabetes treatment (diet, oral antidiabetics or insulin); E (secondary 
analysis): established cardiovascular risk factors (smoking, LDL-cholesterol, 
HDL-cholesterol, systolic blood pressure), cardiovascular medication, 
antihypertensive medication (ACE-inhibitors/ARBs, calcium channel blockers, 
beta blockers and diuretics), and lipid lowering treatment (statins), to model B
Biomarker Model Hazard ratio 95 % confidence 
intervals
p value
sTNFR1 all A 1.47 (1.19–1.83) <0.001
B 1.50 (1.21–1.86) <0.001
C 1.40 (1.11–1.76) 0.004
D 1.49 (1.19–1.86) <0.001
E 1.45 (1.14–1.85) 0.003
Without kidney 
disease
A 1.65 (1.32–2.05) <0.001
B 1.67 (1.34–2.09) <0.001
C 1.58 (1.25–2.00) <0.001
D 1.71 (1.35–2.17) <0.001
E 1.70 (1.28–2.25) <0.001
sTNFR2 A 1.50 (1.18–1.91) 0.001
B 1.52 (1.19–1.94) 0.001
C 1.41 (1.08–1.83) 0.010
D 1.51 (1.18–1.93) 0.001
E 1.58 (1.20–2.09) 0.001
Without kidney 
disease
A 1.65 (1.28–2.13) <0.001
B 1.69 (1.31–2.18) <0.001
C 1.54 (1.16–2.05) 0.003
D 1.66 (1.28–2.15) <0.001
E 1.95 (1.40–2.70) <0.001
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with cancer [33], cardiovascular disease [45], as well as 
kidney disease [46, 47], whether also anti-TNF therapy 
can be beneficial in Type 2 diabetes remains, as far as we 
know, to be studied.
Strengths and limitations
Strengths of our investigation include the prospective 
longitudinal study design, the detailed characterization of 
study participants, and relatively large sample of diabetes 
patients with no loss to follow-up. Limitations include the 
observational design, and extrapolation to other ethnic 
groups. There were also a fairly low rate of incident cardi-
ovascular disease and mortality, limiting the possibility to 
adjust for many factors in the same models, which is why 
we classified the model adjusted for all the cardiovascular 
risk factors as a secondary model. The limited number of 
events also limited us from trying to find a reliable cut-
off for higher risk with sTNFR1 and sTNFR2, and from 
studying ESRD as an outcome. Furthermore, regarding 
the data on microalbuminuria, our study was limited by 
having only a single spot urine sample.
Conclusions
Our data confirm and extend previous studies suggesting 
that sTNFR1 and sTNFR2 are promising biomarkers for 
diabetic kidney disease and cardiovascular risk indepen-
dently of microalbuminuria and baseline kidney function, 
i.e. also in the early stages of type 2 diabetes, as well as 
in early stages of diabetic nephropathy. Further studies 
are warranted to evaluate the future clinical role and use 
of sTNFR1 and sTNFR2 as markers to identify diabetes 
patients with high risk for micro- and macro-vascular 
complications.
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